STOCK TITAN
  1. Home
  2. News
  3. GRFS

Grifols SA - GRFS STOCK NEWS

IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
clinical trial
IMPACT
SENTIMENT
CERS : Nasdaq PINC : Nasdaq GRFS : Nasdaq
Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace
IMPACT
SENTIMENT
GRFS : Nasdaq
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
clinical trial
IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
AI
IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
clinical trial
IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
clinical trial
IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
clinical trial
IMPACT
SENTIMENT
GRFS : Nasdaq
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
clinical trial
IMPACT
SENTIMENT
GRFS : Nasdaq
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
IMPACT
SENTIMENT
GRF : AMEX GRFS : Nasdaq
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
Stock GRFS logo
Grifols SA

Nasdaq:GRFS

GRFS Rankings

N/A Ranked by Market Cap
#792 Ranked by Stock Gains
N/A Ranked by Dividends

GRFS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Spain
Barcelona

About GRFS

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t